Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mack N Barnes

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Human Pathology|November 11, 2003
Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinomaDavid C Chhieng, Cristina Rodriguez-Burford, Lynya I Talley, et al.
Obstetrics and Gynecology|May 2, 2008
Lynch syndrome in women less than 50 years of age with endometrial cancerKellie S Matthews, Jacob M Estes, Michael G Conner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 25, 2002
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenovirusesAnna Kanerva, Minghui Wang, Gerd J Bauerschmitz, et al.
The Journal of Gene Medicine|April 15, 2003
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapyShannon D Barker, Candace J Coolidge, Anna Kanerva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cellsAnna Kanerva, Galina V Mikheeva, Victor Krasnykh, et al.
Cancer Gene Therapy|April 30, 2003
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroidsJohn T Lam, Gerd J Bauerschmitz, Anna Kanerva, et al.
Cancer Research|March 13, 2002
Treatment of ovarian cancer with a tropism modified oncolytic adenovirusGerd J Bauerschmitz, John T Lam, Anna Kanerva, et al.
The Journal of Gene Medicine|October 20, 2004
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapyJohn T Lam, Anna Kanerva, Gerd J Bauerschmitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancerKellie Matthews, Patricia E Noker, Baohong Tian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancerRonald D Alvarez, Warner K Huh, M B Khazaeli, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Human Pathology|November 11, 2003
Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinomaDavid C Chhieng, Cristina Rodriguez-Burford, Lynya I Talley, et al.
Obstetrics and Gynecology|May 2, 2008
Lynch syndrome in women less than 50 years of age with endometrial cancerKellie S Matthews, Jacob M Estes, Michael G Conner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 25, 2002
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenovirusesAnna Kanerva, Minghui Wang, Gerd J Bauerschmitz, et al.
The Journal of Gene Medicine|April 15, 2003
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapyShannon D Barker, Candace J Coolidge, Anna Kanerva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cellsAnna Kanerva, Galina V Mikheeva, Victor Krasnykh, et al.
Cancer Gene Therapy|April 30, 2003
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroidsJohn T Lam, Gerd J Bauerschmitz, Anna Kanerva, et al.
Cancer Research|March 13, 2002
Treatment of ovarian cancer with a tropism modified oncolytic adenovirusGerd J Bauerschmitz, John T Lam, Anna Kanerva, et al.
The Journal of Gene Medicine|October 20, 2004
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapyJohn T Lam, Anna Kanerva, Gerd J Bauerschmitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancerKellie Matthews, Patricia E Noker, Baohong Tian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancerRonald D Alvarez, Warner K Huh, M B Khazaeli, et al.
Pageof 5